Boston Scientific (BSX)Officer sold ~$487K
Vance R Brown, Officer at Boston Scientific, sold ~$487K of Boston Scientific shares.
- ~$487K
- Approx. value · 4,826 sh @ $100.85
- 41K
- Holds after · shares reported
- Traded
- Mar 21, 2025
- Filed
- Mar 24, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 3, 2024InsiderOfficer purchased ~$4.5K of BSX shares in the open market
- Dec 10, 2024InsiderOfficer sold ~$1.8K of BSX shares in the open market
- Feb 3, 2025Insider · 1 personInsiders: 2 sales (~$1.8M)
- Feb 7, 2025InsiderOfficer sold ~$685K of BSX shares in the open market
- Feb 11, 2025InsiderDirector sold ~$1.27M of BSX shares in the open market
- Feb 12, 2025Insider · 3 peopleInsiders: 3 sales (~$3.6M)
- Feb 13, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Feb 14, 2025InsiderOfficer sold ~$128K of BSX shares in the open market
- Feb 18, 2025Insider · 2 peopleInsiders: 3 sales (~$2.1M)
- Feb 19, 2025Insider · 3 peopleInsiders: 3 sales (~$7.6M)
- Feb 21, 2025InsiderOfficer sold ~$505K of BSX shares in the open market
- Feb 24, 2025Insider · 2 peopleInsiders: 2 sales (~$1.9M)
- Feb 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Feb 25, 2025InsiderOfficer sold ~$280K of BSX shares in the open market
- Feb 28, 2025InsiderOfficer sold ~$1M of BSX shares in the open market
- Mar 3, 2025InsiderOfficer sold ~$750K of BSX shares in the open market
- Mar 3, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Mar 4, 2025InsiderOfficer sold ~$50K of BSX shares in the open market
- Mar 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Mar 21, 2025 · this disclosureInsiderOfficer sold ~$487K of BSX shares in the open market
What came next
- Apr 1, 2025InsiderCEO sold ~$16.4M of BSX shares in the open market
- Apr 15, 2025FDAFDA device clearance: Percuflex Ureteral Stent; Percuflex Plus Ureteral Stent; Percuflex Plus SureDrive Steerable Ureteral Stent Set; Contour Ureteral Stent; Contour SureDrive Steer…
- Apr 21, 2025InsiderOfficer sold ~$459K of BSX shares in the open market
- Apr 21, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
- Apr 28, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- May 1, 2025Insider · 2 peopleInsiders: 3 sales (~$18.6M)
- May 5, 2025InsiderOfficer sold ~$478K of BSX shares in the open market
- May 12, 2025CongressDisclosed sale of BSX — reported range $15,001 - $50,000
- May 13, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- May 21, 2025InsiderOfficer sold ~$514K of BSX shares in the open market
- May 28, 2025FDAFDA device clearance: OptiMap System
- May 29, 2025InsiderDirector sold ~$418K of BSX shares in the open market
- Jun 2, 2025Insider · 1 personInsiders: 2 sales (~$17.1M)
- Jun 4, 2025InsiderOfficer sold ~$5.8M of BSX shares in the open market
- Jun 6, 2025FDARecall: Superion IDS Kit Superion Indirect Decompression System 8MM, VF Implant 101-9808 00884662000529 Superion Indirect Decompression System 10MM, VF Implant 101-981…
- Jun 10, 2025FDARecall: Torflex Transseptal Guiding Sheath Kit (TFK-M) TF85-32-63-45 TORFLEX 8.5F 63CM 45DEG TF85-32-63-55 TORFLEX 8.5F 63CM 55DEG Used for the percutaneous introducti…
- Jun 10, 2025FDARecall: VersaCross Access Solution (VXSK), Product Description and ID: VXSK (180J RF WIRE 63CM/45DEG/D0) VXSK0101 VXSK (180J RF WIRE 63CM/45DEG/D1) VXSK0102 VXSK (180J…
- Jun 10, 2025FDARecall: VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product ID VXW0002 Device approved and commercialized in Japan only.
- Jun 10, 2025FDARecall: VersaCross Transseptal Sheath Kit (VXS) Product Description/IDs VXS0201 VXS 63CM/45DEG/D0 SHEATH VXS2112 VERSACROSS SHEATH (63CM 45DEG D0)-J Used for the percu…
- Jun 11, 2025FDAFDA device clearance: Rezum System
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Boston Scientific
For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.
Other recent filings by Vance R Brown, SVP, GC and Corp. Secretary
- SEC Form 4 at Boston Scientific (BSX)May 22, 2025
- SEC Form 4 at Boston Scientific (BSX)Apr 22, 2025
- SEC Form 4 at Boston Scientific (BSX)Feb 21, 2025
The full history of Vance R Brown, SVP, GC and Corp. Secretary is on the profile page.
How this filing works
Other disclosures at Boston Scientific
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- House Clerk periodic transaction reportSep 25, 2026
Everything OQRO holds on this company is on its BSX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
